U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 2

2.
Figure 2

Figure 2. From: Stellarex drug‐coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12‐Month results from a prospective, multicenter, single‐arm study.

(A) Freedom from a primary safety event through 1 year: the freedom from a primary safety event at day 365 was 94.8% and 92.1% at the end of the follow‐up window (day 395). (B) Freedom from loss of primary patency through 1 year: the primary patency rate at day 365 was 81.4% and 69.1% at the end of the follow‐up window (day 395). (C) Freedom from CD‐TLR through 1 year: freedom from CD‐TLR at day 365 was 94.8% and 92.1% the end of the follow‐up window (day 395). (D) Freedom from loss of primary patency rates of patients with diabetes and patients without diabetes: primary patency rates of patients with diabetes (blue line) was not different than patients without diabetes (red line) (day 365 estimates: 81.0% vs. 81.5%, P = 0.9717 by log rank). Rates at the end of the follow‐up window should be interpreted with caution as the number of patients at risk is low due to subjects being censored prior to day 395, at the time of the 12‐month visit [Color figure can be viewed at wileyonlinelibrary.com]

Herman Schroë, et al. Catheter Cardiovasc Interv. 2018 Feb 15;91(3):497-504.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center